Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash.

[1]  M. Milivojevic,et al.  SERUM PROTEIN MARKERS FOR EARLY DETECTION OF OVARIAN CANCER , 2009 .

[2]  D. Ward,et al.  Diagnostic markers for early detection of ovarian cancer (Clinical Cancer Research (2008) 14, (1065-1072)) , 2008 .

[3]  P. Sabbatini,et al.  A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. , 2008, Gynecologic oncology.

[4]  B. Vanderhyden,et al.  Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Daniel J. Freeman,et al.  Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. , 2008, Clinical colorectal cancer.

[6]  C. Sawyers.  The cancer biomarker problem , 2008, Nature.

[7]  A. Baron,et al.  Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. , 2008, Biochimica et biophysica acta.

[8]  P. LoRusso,et al.  Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Ward,et al.  Diagnostic Markers for Early Detection of Ovarian Cancer , 2008, Clinical Cancer Research.

[10]  Thorsten Verch,et al.  The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. , 2008, Gynecologic oncology.

[11]  A. Lièvre,et al.  KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  F. Cavalli,et al.  PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients , 2007, British Journal of Cancer.

[13]  S. Skates,et al.  Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin. , 2007, Gynecologic oncology.

[14]  S. Waggoner,et al.  A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study. , 2007, Gynecologic oncology.

[15]  F. Ciardiello,et al.  Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), Pharmacodynamic (PD) and efficacy data , 2007 .

[16]  W. Carney,et al.  Elevated plasma tissue inhibitor of metalloproteinase‐1 level predicts decreased response and survival in metastatic breast cancer , 2007, Cancer.

[17]  Manuel Hidalgo,et al.  Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Molly Brewer,et al.  Prevention and early detection of ovarian cancer: mission impossible? , 2007, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[19]  H. Burris,et al.  A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. , 2007, Gynecologic oncology.

[20]  Suzanne F. Jones,et al.  A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing , 2007, Clinical Cancer Research.

[21]  Faina Linkov,et al.  Early Detection of Head and Neck Cancer: Development of a Novel Screening Tool Using Multiplexed Immunobead-Based Biomarker Profiling , 2007, Cancer Epidemiology Biomarkers & Prevention.

[22]  A. Lokshin,et al.  Multiple biomarker panels for early detection of ovarian cancer. , 2006, Future oncology.

[23]  U. Löhrs,et al.  KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. , 2006, Gynecologic oncology.

[24]  H. R. Bergen,et al.  Elevated levels of phosphorylated fibrinogen-α-isoforms and differential expression of other post-translationally modified proteins in the plasma of ovarian cancer patients , 2006 .

[25]  W. Carney,et al.  Serum epidermal growth factor receptor/HER‐2 predicts poor survival in patients with metastatic breast cancer , 2006, Cancer.

[26]  D. Landsittel,et al.  Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. , 2006, Gynecologic oncology.

[27]  M. Bookman,et al.  GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[29]  Nicole Urban,et al.  Bead-Based ELISA for Validation of Ovarian Cancer Early Detection Markers , 2006, Clinical Cancer Research.

[30]  A. Scorilas,et al.  Kallikreins as Markers of Disseminated Tumour Cells in Ovarian Cancer – A Pilot Study , 2006, Tumor Biology.

[31]  S. Clarke,et al.  A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer , 2006, British Journal of Cancer.

[32]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.

[33]  Yinhua Yu,et al.  Potential markers that complement expression of CA125 in epithelial ovarian cancer. , 2005, Gynecologic oncology.

[34]  Victor G Zgoda,et al.  Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1 , 2005, Proteomics.

[35]  K A Baggerly,et al.  New tumor markers: CA125 and beyond , 2005, International Journal of Gynecologic Cancer.

[36]  A. Godwin,et al.  Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study , 2005, Clinical Cancer Research.

[37]  R. Perez-soler,et al.  Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  William L. Bigbee,et al.  Multiplexed Immunobead-Based Cytokine Profiling for Early Detection of Ovarian Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.

[39]  C. Sezgin,et al.  Predictive value of serum interleukin‐8 levels in ovarian cancer patients treated with paclitaxel‐containing regimens , 2005, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[40]  E. Susman.  Rash correlates with tumour response after cetuximab. , 2004, The Lancet. Oncology.

[41]  Steven J Skates,et al.  Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  B. Monk,et al.  Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy , 2004, Cancer.

[43]  R. Edwards,et al.  Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study , 2004, International Journal of Gynecologic Cancer.

[44]  E. Daraï,et al.  Serum and cyst fluid levels of interleukin (IL) -6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours. , 2003, Human reproduction.

[45]  Gordon B Mills,et al.  Overexpression of kallikrein 10 in epithelial ovarian carcinomas. , 2003, Gynecologic oncology.

[46]  Michèl Schummer,et al.  The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. , 2003, Cancer research.

[47]  R. Bast,et al.  Status of tumor markers in ovarian cancer screening. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  Ignace Vergote,et al.  The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. , 2003, Cancer research.

[49]  W. Carney,et al.  Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Roy S Herbst,et al.  Monoclonal antibodies to target epidermal growth factor receptor–positive tumors , 2002, Cancer.

[51]  A. Gadducci,et al.  The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer , 2001, International Journal of Gynecologic Cancer.

[52]  Christine Brun,et al.  In silico prediction of protein-protein interactions in human macrophages , 2001, BMC Research Notes.

[53]  A. Scorilas,et al.  Human kallikrein 10: a novel tumor marker for ovarian carcinoma? , 2001, Clinica chimica acta; international journal of clinical chemistry.

[54]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[55]  U. Matulonis,et al.  Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. , 2000, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[56]  U. Testa,et al.  IL-6, M-CSF and IAP Cytokines in Ovarian Cancer: Simultaneous Assessment of Serum Levels , 1999, Oncology.

[57]  L. M. Strawn,et al.  Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials. , 1998, Expert opinion on investigational drugs.

[58]  C. Kainz,et al.  Serum evaluation of interleukin 6 in ovarian cancer patients. , 1997, Gynecologic oncology.

[59]  Chopra,et al.  Angiogenin, interleukins, and growth-factor levels in serum of patients with ovarian cancer: correlation with angiogenesis. , 1996, The cancer journal from Scientific American.

[60]  C. Peschle,et al.  Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. , 1995, British Journal of Cancer.

[61]  W. Schröder,et al.  Concomitant measurements of interleukin-6 (IL-6) in serum and peritoneal fluid of patients with benign and malignant ovarian tumors. , 1994, European journal of obstetrics, gynecology, and reproductive biology.

[62]  L. Twiggs,et al.  Serum and ascitic fluid levels of interleukin‐1, interleukin‐6, and tumor necrosis factor‐alpha in patients with ovarian epithelial cancer , 1993, Cancer.

[63]  C. Perez,et al.  Principles and Practice of Gynecologic Oncology , 1992 .

[64]  J. Berek,et al.  Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. , 1991, American journal of obstetrics and gynecology.

[65]  Michael Cross,et al.  Growth factors in development, transformation, and tumorigenesis , 1991, Cell.

[66]  J. Mendelsohn,et al.  Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[67]  F.A.M. Bordonaba,et al.  Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer , 2009 .

[68]  U. Coşkun,et al.  Clinical significance of serum MMP-2 and MMP-7 in patients with ovarian cancer , 2008, Medical oncology.

[69]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[70]  N. Hanna.  Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study , 2007 .

[71]  H. R. Bergen,et al.  Elevated levels of phosphorylated fibrinogen-alpha-isoforms and differential expression of other post-translationally modified proteins in the plasma of ovarian cancer patients. , 2006, Journal of proteome research.

[72]  Z. Hua.  Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer , 2006 .

[73]  L. Saltz,et al.  The presence and intensity of the cetuximab- induced acne-like rash predicts increased survival in studies across multiple malignances , 2003 .